Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + lobaplatin versus docetaxel + gemcitabine for recurrent or metastatic breast cancer
ChiCTR-IPR-14005633Phase 4Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Docetaxel + lobaplatin with Docetaxel + gemcitabine (2 arms). Primary endpoint: Disease control rate. Started Nov 2014; status: recruiting.
02
Drugs
docetaxellobaplatingemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-IPR-14005633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005633.